News

Sygnis AG Enters into Collaboration Agreement with ECACC for Licensing


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Sygnis AG Enters into Collaboration Agreement with ECACC for Licensing and Distribution of Caco-2 Cell Line

 22/09/2016

> Collaboration significantly expands SYGNIS’ Caco-2 business

> SYGNIS already started commercialization of Caco-2 cell line in Europe


SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that Navicyte Scientific, part of SYGNIS Group in the US, and the European Collection of Authenticated Cell Cultures (ECACC), part of Public Health England, an agency of the United Kingdom Department of Health have entered into a collaboration agreement for licensing and distributing the Caco-2 cell line to commercial companies. Under the collaboration, ECACC will organize that companies obtain the license for the use of the Caco-2 cell line from SYGNIS in the US and afterwards will provide the Caco-2 materials directly.

“We are very happy about this collaboration agreement with ECACC,” Pilar de la Huerta, Co-CEO and CFO of SYGNIS AG commented. “Up to now, the majority of our Caco-2 business has been in the US. This new collaboration will expand our Caco-2 activities to Europe and increase the commercialization potential for SYGNIS, as ECACC is very active in the distribution of cell lines to researchers. ECACC has a large customer data base and they will include our Caco-2 cell line in their project developments.”

Caco-2 cells were developed by the Memorial Sloan Kettering Cancer Center (MSKCC) and are now available from ECACC. ECACC is authorized to distribute these cells to the scientific community for the use in research and SYGNIS currently holds an exclusive license from the MSKCC for the commercial use of the Caco-2 cell line. The primary use of this cell line is in pharmaceutical drug development, particularly for absorption of orally bioavailable molecules and transporter studies. The Caco-2 assay is well characterized and is the recognized gold standard for absorption assays. It is part of many standard preclinical (ADME) substance characterization packages used by the pharmaceutical industry.


For further information, please contact:

SYGNIS AG
Pilar de la Huerta
Co-CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com

MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
Madrid, Spain/Heidelberg, Germany


SYGNIS AG, Waldhofer Str. 104, 69123 Heidelberg, Germany, www.sygnis.de, Tel.: + 49-6221- 3540-125, Fax: +49-6221- 3540-127


About SYGNIS AG: www.sygnis.com

SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).


### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###

© Catalyst Innovation Portal 2019